We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug & Device Products
FDAnews Books Library
Events
Form 483s Database
Publications
Webinar Training Pass
eCFR and Guidances
Books
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Marijo B. Kambere
Marijo B. Kambere
Products
PRODUCTS
Yibin Lihao Bio-technical Co., Ltd.
Marijo B. Kambere
Price:
$117.00
View
Hisun Pharmaceutical (Hangzhou) Co., Ltd.
Marijo B. Kambere
Price:
$117.00
View
Enantiotech Co., Ltd.
Marijo B. Kambere
Price:
$117.00
View
OXARC, Inc.
Marijo B. Kambere
Price:
$117.00
View
Abbott AMO (Hangzhou) Co., Ltd.
Peter E. Baker
and
Marijo B. Kambere
Price:
$117.00
View
Chongqing Pharmaceutical Research Institute Co., Ltd.
Peter E. Baker
and
Marijo B. Kambere
Price:
$117.00
View
Option Care Enterprises, Inc.
Gerard De Leon
,
Marijo B. Kambere
, and
Sangeeta M. Khurana
Price:
$117.00
View
Bend Research, Inc.
Christopher Czajka
,
Marijo B. Kambere
,
George Lunn
,
Anita Narula
, and
Robert D. Tollefsen
Price:
$117.00
View
Kirkman Laboratories, Inc.
Marijo B. Kambere
and
Marie P. Kelly-Doggett
Price:
$117.00
View
Upcoming Events
24
May
Powering an Effective Oversight Strategy with Clinical and Operational Insights
25
May
2022 WCG Avoca Quality & Innovation Summit: Own the Future
21
Jun
Medical Device Reporting: Best Practices and Common Pitfalls
22
Jun
Meet CDRH’s New Strategic Priorities: Where the Center is Headed and How Devicemakers Can Keep Up
28
Jun
Effective Root Cause Analysis and CAPA Investigations for the Life Sciences
Featured Products
Biological Risk Evaluation and Management for Medical Devices
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
Featured Stories
Linear Health Sciences Gets FDA Clearance for Its Orchid Safety Release Valve
Roche’s Faricimab Gains UK Approval Via International Program
Becton Dickinson Gets FDA Clearance for Its Molecular Diagnostic Platform
Bayer Backs Out of $670 Million Collaboration Deal With Atara
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
